Sat Out Arrowhead Pharmaceuticals' Rally? Here Is What Holders Saw

If you only skimmed the headlines on Arrowhead Pharmaceuticals back in October 2025, the split between bullish and bearish analyst targets already looked stark. For Arrowhead Pharmaceuticals shareholders, the return over the past year was 52.7%, including dividends. If you had been deciding on 23 October 2025 whether to buy, the real question was whether cost advantages and partnership cash flows outweighed the heavy reliance on future RNAi approvals and rich P/E assumptions.

This theme extends beyond Arrowhead Pharmaceuticals. See which of 34 healthcare AI stocks may still merit a closer look.

The Argument You Would Have Been Weighing On Arrowhead Pharmaceuticals

The shares cost US$37.35 at the start of the period, so anyone looking at Arrowhead Pharmaceuticals had to pick between two very different stories.

On the optimistic side, the bullish view pointed to a Fair Value of US$46.15, essentially a price implied by expectations that cost advantages, partnership income and a future profit margin of 14.2% could support a rich future P/E of 166.8x over roughly three years.

The cautious camp anchored on a Fair Value of US$17, built on concerns that stricter reimbursement, pressure from generics and gene editing, and revenue growth assumed to fall 48.6% each year would force Arrowhead Pharmaceuticals into a far more demanding future P/E of 277.8x.

What The Results Changed For Arrowhead Pharmaceuticals

The clearest new datapoint for Arrowhead Pharmaceuticals was plozasiran’s strong Phase 3 showing in severe hypertriglyceridemia, plus EU approval and rollout of REDEMPLO for familial chylomicronemia syndrome. That supported the optimistic case about the RNAi pipeline and partnerships. Yet Q3 revenue moved from US$27.767 million to US$75.253 million while the business still reported a larger net loss, so profitability remained unproven. Overall, the evidence cut both ways.

The lesson is simple. When a story hinges on future margins, treat each quarter as a check on that promise and track whether rising product and partnership revenue is turning into shrinking losses, not just higher top line.

What Arrowhead Pharmaceuticals’ Price Now Assumes

Arrowhead Pharmaceuticals now trades at US$58.02 after a 52.7% gain over the past year. The selected Narrative’s Fair Value sits above the current price based on its own assumptions about the cardiometabolic and CNS pipeline.

That view leans on plozasiran execution, broader cardiometabolic reach and partner funded programs that the Narrative argues today’s price does not fully credit.

"ARO DIMER PA has produced single dose reductions of more than 80% in APOC3 and more than 70% in PCSK9 with meaningful effects on LDL C, triglycerides, non HDL C and ApoB in mixed hyperlipidemia patients. This opens a path to a dual target therapy for roughly 20 million U.S. patients that could add a separate revenue stream and improve product mix."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Looking One Step Beyond Arrowhead

Arrowhead leans on potential drug approvals and partnership economics. Your watchlist does not have to stop there.

Major treatment gaps in cancer, immunology and brain disorders still require new therapies. Another large healthcare group is investing considerable capital into that search.

It spreads research across established products and late stage programs, instead of relying on a single blockbuster. That breadth can change how setbacks in one area affect the enterprise.

Complex procedures are also moving toward devices and systems that improve precision and efficiency in the operating room. If that trend holds, this second business could reshape your healthcare mix.

One Narrative has already put a figure on it. → Uncover the company trading 18% below one Narrative's Fair Value

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com